NGOs Urge EU Ministers To Resist 'Industry Pressure' and Reform RnD Model, Raise Regulatory Standards
This article was originally published in SRA
Executive Summary
A group of 25 civil society bodies and NGOs have called on EU member states to resist what they describe as 'pressure from the pharmaceutical industry to eliminate critical elements of proposed EU Council Conclusions' that are intended to improve the balance between intellectual property measures designed to encourage innovation and the need to ensure patients have access to affordable medicines1.
You may also be interested in...
MEPs Slate EU Industry Practices In Report On Barriers To Medicines Access
The European Parliament’s environment and public health committee has produced a set of recommendations for a new approach to tackling barriers to medicines in the EU. There’s a particular focus on pricing strategies, intellectual property, and delays to generic competition.
'Don't Compromise The Pharma Innovation System,' Says Outgoing IFPMA Head Thomas Cueni
Thomas Cueni is stepping down after seven years at the helm of the International Federation of Pharmaceutical Manufacturers and Associations. In an interview with the Pink Sheet ahead of his retirement, he reflects on the proposed pandemic treaty, what still needs to be done to ensure equitable access to medicines, the importance of tackling AMR, moves towards regulatory reliance – and what his post-IFPMA life might look like.
EU Warns Of Life-Threatening Interactions Between Paxlovid & Some Immunosuppressants
The EU’s pharmacovigilance committee says that a review of the available evidence showed that in several cases, blood levels of immunosuppressants increased rapidly to toxic levels in patients who were taking the Pfizer drug.